Shots:
- Minghui has granted Qilu exclusive rights to develop, manufacture & market MHB088C in Greater China (incl. Mainland China, Hong Kong, Macau, & Taiwan)
- As per the deal, Minghui will receive ~$185.9M (CN¥ 1.345B) incl. $38.7M as upfront & near-term milestone payments & ~$147.2M in development, regulatory & sales milestones, plus double-digit net sales-based royalties; Minghui to retain rights in non-licensed areas
- MHB088C (B7-H3 ADC), developed via Minghui’s SuperTopoi ADC platform, is in an ongoing P-I/II trial (over 300 pts) for advanced or metastatic solid tumors; subgroup data in SCLC & mCRPC to be shared at ASCO 2025. A P-III trial in relapsed SCLC is initiated in China, with 1st pts enrolling in a couple of wks.
Ref: PRNewswire | Image: ViVerita Therapeutics and Boehringer Ingelheim
Related News:- ViVerita Therapeutics Collaborates with Boehringer Ingelheim to Accelerate Discovery of Novel Therapeutic Targets in Oncology
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click Here for Full Press Release
